Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Danger in the vapor? ECMO for adolescents with status asthmaticus after vaping.

Bradford LE, Rebuli ME, Ring BJ, Jaspers I, Clement KC, Loughlin CE.

J Asthma. 2019 Jul 27:1-5. doi: 10.1080/02770903.2019.1643361. [Epub ahead of print]

PMID:
31352844
2.

Low-Turnover Drug Molecules: A Current Challenge for Drug Metabolism Scientists.

Hutzler JM, Ring BJ, Anderson SR.

Drug Metab Dispos. 2015 Dec;43(12):1917-28. doi: 10.1124/dmd.115.066431. Epub 2015 Sep 11. Review.

PMID:
26363026
3.

Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.

Baker JA, Wickremsinhe ER, Li CH, Oluyedun OA, Dantzig AH, Hall SD, Qian YW, Ring BJ, Wrighton SA, Guo Y.

Drug Metab Dispos. 2013 Mar;41(3):541-5. doi: 10.1124/dmd.112.048769. Epub 2012 Dec 10.

PMID:
23230131
4.

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance.

Ring BJ, Chien JY, Adkison KK, Jones HM, Rowland M, Jones RD, Yates JW, Ku MS, Gibson CR, He H, Vuppugalla R, Marathe P, Fischer V, Dutta S, Sinha VK, Björnsson T, Lavé T, Poulin P.

J Pharm Sci. 2011 Oct;100(10):4090-110. doi: 10.1002/jps.22552. Epub 2011 May 3.

PMID:
21541938
5.

PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.

Poulin P, Jones RD, Jones HM, Gibson CR, Rowland M, Chien JY, Ring BJ, Adkison KK, Ku MS, He H, Vuppugalla R, Marathe P, Fischer V, Dutta S, Sinha VK, Björnsson T, Lavé T, Yates JW.

J Pharm Sci. 2011 Oct;100(10):4127-57. doi: 10.1002/jps.22550. Epub 2011 May 3.

PMID:
21541937
6.

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasets.

Poulin P, Jones HM, Jones RD, Yates JW, Gibson CR, Chien JY, Ring BJ, Adkison KK, He H, Vuppugalla R, Marathe P, Fischer V, Dutta S, Sinha VK, Björnsson T, Lavé T, Ku MS.

J Pharm Sci. 2011 Oct;100(10):4050-73. doi: 10.1002/jps.22554. Epub 2011 Apr 26.

PMID:
21523782
7.

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach.

Vuppugalla R, Marathe P, He H, Jones RD, Yates JW, Jones HM, Gibson CR, Chien JY, Ring BJ, Adkison KK, Ku MS, Fischer V, Dutta S, Sinha VK, Björnsson T, Lavé T, Poulin P.

J Pharm Sci. 2011 Oct;100(10):4111-26. doi: 10.1002/jps.22551. Epub 2011 Apr 7.

PMID:
21480234
8.

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution.

Jones RD, Jones HM, Rowland M, Gibson CR, Yates JW, Chien JY, Ring BJ, Adkison KK, Ku MS, He H, Vuppugalla R, Marathe P, Fischer V, Dutta S, Sinha VK, Björnsson T, Lavé T, Poulin P.

J Pharm Sci. 2011 Oct;100(10):4074-89. doi: 10.1002/jps.22553. Epub 2011 Mar 30.

PMID:
21452299
9.

Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans.

Yi P, Hadden C, Kulanthaivel P, Calvert N, Annes W, Brown T, Barbuch RJ, Chaudhary A, Ayan-Oshodi MA, Ring BJ.

Drug Metab Dispos. 2010 Apr;38(4):554-65. doi: 10.1124/dmd.109.030841. Epub 2010 Jan 14.

PMID:
20075192
10.

Predictions of the in vivo clearance of drugs from rate of loss using human liver microsomes for phase I and phase II biotransformations.

Mohutsky MA, Chien JY, Ring BJ, Wrighton SA.

Pharm Res. 2006 Apr;23(4):654-62. Epub 2006 Mar 24.

PMID:
16550474
11.

Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450.

Rehmel JL, Eckstein JA, Farid NA, Heim JB, Kasper SC, Kurihara A, Wrighton SA, Ring BJ.

Drug Metab Dispos. 2006 Apr;34(4):600-7. Epub 2006 Jan 13.

PMID:
16415119
12.

Clinical pharmacokinetics of atomoxetine.

Sauer JM, Ring BJ, Witcher JW.

Clin Pharmacokinet. 2005;44(6):571-90. Review.

PMID:
15910008
13.

Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo.

Ring BJ, Patterson BE, Mitchell MI, Vandenbranden M, Gillespie J, Bedding AW, Jewell H, Payne CD, Forgue ST, Eckstein J, Wrighton SA, Phillips DL.

Clin Pharmacol Ther. 2005 Jan;77(1):63-75.

PMID:
15637532
14.

The effect of incubation conditions on the enzyme kinetics of udp-glucuronosyltransferases.

Soars MG, Ring BJ, Wrighton SA.

Drug Metab Dispos. 2003 Jun;31(6):762-7.

PMID:
12756209
15.

A novel testosterone 6 beta-hydroxylase activity assay for the study of CYP3A-mediated metabolism, inhibition, and induction in vitro.

Fayer JL, Petullo DM, Ring BJ, Wrighton SA, Ruterbories KJ.

J Pharmacol Toxicol Methods. 2001 Sep-Oct;46(2):117-23.

PMID:
12481849
16.

Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes.

Williams JA, Ring BJ, Cantrell VE, Campanale K, Jones DR, Hall SD, Wrighton SA.

Drug Metab Dispos. 2002 Nov;30(11):1266-73.

PMID:
12386134
17.

The interactions of a selective protein kinase C beta inhibitor with the human cytochromes P450.

Ring BJ, Gillespie JS, Binkley SN, Campanale KM, Wrighton SA.

Drug Metab Dispos. 2002 Sep;30(9):957-61.

PMID:
12167559
18.

Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.

Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA.

Drug Metab Dispos. 2002 Aug;30(8):883-91.

PMID:
12124305
19.

Identification of the human cytochromes P450 responsible for atomoxetine metabolism.

Ring BJ, Gillespie JS, Eckstein JA, Wrighton SA.

Drug Metab Dispos. 2002 Mar;30(3):319-23.

PMID:
11854152
20.

Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine.

Ring BJ, Eckstein JA, Gillespie JS, Binkley SN, VandenBranden M, Wrighton SA.

J Pharmacol Exp Ther. 2001 Jun;297(3):1044-50.

PMID:
11356927
21.

A population approach to enzyme characterization and identification: application to phenacetin O-deethylation.

Belle DJ, Ring BJ, Allerheiligen SR, Heathman MA, O'Brien LM, Sinha V, Roskos LK, Wrighton SA.

Pharm Res. 2000 Dec;17(12):1531-6.

PMID:
11303964
22.

Present and future in vitro approaches for drug metabolism.

Ekins S, Ring BJ, Grace J, McRobie-Belle DJ, Wrighton SA.

J Pharmacol Toxicol Methods. 2000 Jul-Aug;44(1):313-24. Review.

PMID:
11274898
23.

Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors.

Ekins S, Bravi G, Binkley S, Gillespie JS, Ring BJ, Wikel JH, Wrighton SA.

Drug Metab Dispos. 2000 Aug;28(8):994-1002.

PMID:
10901712
24.

Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors.

Ekins S, Bravi G, Binkley S, Gillespie JS, Ring BJ, Wikel JH, Wrighton SA.

Pharmacogenetics. 1999 Aug;9(4):477-89.

PMID:
10780267
25.

Flavin-containing monooxygenase-mediated N-oxidation of the M(1)-muscarinic agonist xanomeline.

Ring BJ, Wrighton SA, Aldridge SL, Hansen K, Haehner B, Shipley LA.

Drug Metab Dispos. 1999 Oct;27(10):1099-103.

PMID:
10497134
26.

Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors.

Ekins S, Bravi G, Binkley S, Gillespie JS, Ring BJ, Wikel JH, Wrighton SA.

J Pharmacol Exp Ther. 1999 Jul;290(1):429-38.

PMID:
10381809
27.

Predicting drug interactions and pharmacokinetic variability with in vitro methods: the olanzapine experience.

Wrighton SA, Ring BJ.

Drug Metab Rev. 1999 Feb;31(1):15-28. Review. No abstract available.

PMID:
10065363
28.
29.

Autoactivation and activation of the cytochrome P450s.

Ekins S, Ring BJ, Binkley SN, Hall SD, Wrighton SA.

Int J Clin Pharmacol Ther. 1998 Dec;36(12):642-51.

PMID:
9877001
30.

Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6.

Ekins S, Bravi G, Ring BJ, Gillespie TA, Gillespie JS, Vandenbranden M, Wrighton SA, Wikel JH.

J Pharmacol Exp Ther. 1999 Jan;288(1):21-9.

PMID:
9862748
31.

Alterations of the catalytic activities of drug-metabolizing enzymes in cultures of human liver slices.

VandenBranden M, Wrighton SA, Ekins S, Gillespie JS, Binkley SN, Ring BJ, Gadberry MG, Mullins DC, Strom SC, Jensen CB.

Drug Metab Dispos. 1998 Nov;26(11):1063-8.

PMID:
9806947
32.

Further characterization of the expression in liver and catalytic activity of CYP2B6.

Ekins S, Vandenbranden M, Ring BJ, Gillespie JS, Yang TJ, Gelboin HV, Wrighton SA.

J Pharmacol Exp Ther. 1998 Sep;286(3):1253-9.

PMID:
9732386
33.

Examination of purported probes of human CYP2B6.

Ekins S, VandenBranden M, Ring BJ, Wrighton SA.

Pharmacogenetics. 1997 Jun;7(3):165-79.

PMID:
9241656
34.

The human drug metabolizing cytochromes P450.

Wrighton SA, VandenBranden M, Ring BJ.

J Pharmacokinet Biopharm. 1996 Oct;24(5):461-73. Review.

PMID:
9131485
35.

In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A.

Ring BJ, Binkley SN, Vandenbranden M, Wrighton SA.

Br J Clin Pharmacol. 1996 Mar;41(3):181-6.

36.

Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor.

VandenBranden M, Ring BJ, Binkley SN, Wrighton SA.

Pharmacogenetics. 1996 Feb;6(1):81-91.

PMID:
8845864
37.

Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine.

Ring BJ, Catlow J, Lindsay TJ, Gillespie T, Roskos LK, Cerimele BJ, Swanson SP, Hamman MA, Wrighton SA.

J Pharmacol Exp Ther. 1996 Feb;276(2):658-66.

PMID:
8632334
38.

Effect of fluoxetine, norfluoxetine, sertraline and desmethyl sertraline on human CYP3A catalyzed 1'-hydroxy midazolam formation in vitro.

Ring BJ, Binkley SN, Roskos L, Wrighton SA.

J Pharmacol Exp Ther. 1995 Dec;275(3):1131-5.

PMID:
8531073
39.

The use of in vitro metabolism techniques in the planning and interpretation of drug safety studies.

Wrighton SA, Ring BJ, VandenBranden M.

Toxicol Pathol. 1995 Mar-Apr;23(2):199-208. Review.

PMID:
7569675
40.
41.

In vitro metabolism of zatosetron. Interspecies comparison and role of CYP 3A.

Ring BJ, Parli CJ, George MC, Wrighton SA.

Drug Metab Dispos. 1994 May-Jun;22(3):352-7.

PMID:
8070310
42.

In vitro methods for assessing human hepatic drug metabolism: their use in drug development.

Wrighton SA, Vandenbranden M, Stevens JC, Shipley LA, Ring BJ, Rettie AE, Cashman JR.

Drug Metab Rev. 1993;25(4):453-84. Review. No abstract available. Erratum in: Drug Metab Rev 1994;26(1-2):483.

PMID:
8313838
43.

The effect of diet and litter size on the elimination of 2,4,5,2',4',5'-[14C]hexachlorobiphenyl from lactating mice.

Ring BJ, Seitz KR, Gallenberg LA, Vodicnik MJ.

Toxicol Appl Pharmacol. 1990 Jun 1;104(1):9-16.

PMID:
2113721
44.

The influence of time of maternal exposure to 2,4,5,2',4',5'-hexachlorobiphenyl on its accumulation in their nursing offspring.

Gallenberg LA, Ring BJ, Vodicnik MJ.

Toxicol Appl Pharmacol. 1990 Jun 1;104(1):1-8.

PMID:
2113719
45.

Computed temperature distributions around ectatic capillaries exposed to yellow (578 nm) laser light.

Pickering JW, Butler PH, Ring BJ, Walker EP.

Phys Med Biol. 1989 Sep;34(9):1247-58.

PMID:
2798560
46.

Identification of a polymorphically expressed member of the human cytochrome P-450III family.

Wrighton SA, Ring BJ, Watkins PB, VandenBranden M.

Mol Pharmacol. 1989 Jul;36(1):97-105.

PMID:
2747634
47.

Thermal profiles of blood vessels heated by a laser.

Pickering JW, Butler PH, Ring BJ, Walker EP.

Australas Phys Eng Sci Med. 1989 Mar;12(1):11-5.

PMID:
2705959
48.

Transfer of 2,4,5,2',4',5'-hexachlorobiphenyl across the in situ perfused guinea pig placenta.

Ring BJ, Seitz KR, Vodicnik MJ.

Toxicol Appl Pharmacol. 1988 Oct;96(1):7-13.

PMID:
3142100
49.

Chronic effects of fractionated renal irradiation on the pharmacokinetics of intravenous methotrexate.

Holcenberg JS, Moulder JE, Karmen BA, Krailo MD, Fish BL, Ring BJ, Adams S.

Int J Radiat Oncol Biol Phys. 1987 May;13(5):759-64.

PMID:
3570900
50.

Influence of lipolysis on the mobilization of 2,4,5,2'4',5'-hexachlorobiphenyl from adipocytes in vitro.

Gallenberg LA, Ring BJ, Vodicnik MJ.

J Toxicol Environ Health. 1987;20(1-2):163-71.

PMID:
3100817

Supplemental Content

Support Center